The global renal denervation market size is anticipated to reach USD 3.62 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 40.2% from 2024 to 2030. Growing incidences of hypertension, changing lifestyle, and enduring effect of renal denervation procedure are the key factors driving market.
Increasing cases of uncontrolled and drug-resistant hypertension are expected to fuel the demand for renal denervation. As per the data published in November 2016, by the Centre for Disease Control and Prevention (CDC), about 75 million people in U.S. have high blood pressure. High blood pressure increases the risk of stroke and heart disease, a leading cause of deaths in America. Complications of hypertension causes 9.4 million deaths each year. Furthermore, hypertension is responsible for at least 51% of deaths due to stroke and 45% of deaths due to heart disease.
The renal denervation market in developed economies, such as U.K., France, and Italy, is comparatively mature owing to the presence of key companies in these countries and high demand for such products. Europe commanded the largest share owing to the rise in number of drug-resistant hypertension cases and technological advancements.
On the other hand, developing countries of Asia and Latin America are expected to witness the fastest growth due to economic growth and increased consumer disposable income. Further, growing elderly population coupled with high prevalence of diabetes in these region sis anticipated to propel the region’s development.
Request a free sample copy or view report summary: Renal Denervation Market Report
Radiofrequency based technology dominated the market with a 74.6% share in 2023, primarily due to its effectiveness and advancements in treating resistant hypertension.
Ultrasound renal denervation is expected to register the fastest CAGR during the forecast period owing to its enhanced safety and efficacy compared to other methods.
Europe renal denervation market secured the dominant share with 45.6% of the global revenue in 2023 owing to the high prevalence of hypertension and cardiovascular diseases.
Grand View Research has segmented the global renal denervation market report based on technology, and region:
Renal Denervation Technology Outlook (Revenue, USD Million, 2018 - 2030)
Radiofrequency based
Ultrasound based
Micro-Infusion based
Renal Denervation Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Sweden
Norway
Denmark
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
UAE
South Africa
Kuwait
Saudi Arabia
List Of Key Players in the Renal Denervation Market
Medtronic
Abbott
Ablative Solutions, Inc
Mercator MedSystems, Inc.
Otsuka Medical Devices Co., Ltd.
Boston Scientific Corporation
SympleSurgical, Inc.
Johnson & Johnson Services, Inc.
"The quality of research they have done for us has been excellent..."